TJ101 / Phrontline Biopharma - LARVOL DELTA

Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of solid cancers (AACR 2025) - "In summary, TJ101 is a promising bispecific ADC with highly potent anti-tumor efficacy across multiple solid cancer types and preferable toxicity profiles, enabling an increased therapeutic index. Additionally, the dual-targeting approach of TJ101 offers a significant advantage in overcoming potential tumor resistance that may arise during future clinical applications."

Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD276 • EGFR